Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents

Simple item page
dc.contributor.authorMolina-Cuadrado, Emilio
dc.contributor.authorMateo-Carrrasco, Hector
dc.contributor.authorCollado, Antonio
dc.contributor.authorMartin, Marta Casado
dc.contributor.authoraffiliation[Molina-Cuadrado, Emilio] Torrecardenas Univ Hosp, Pharm Dept, Federico Garcia Lorca 69 5B, Almeria, Spain
dc.contributor.authoraffiliation[Mateo-Carrrasco, Hector] Royal Marsden Hosp, Pharm Dept, London, England
dc.contributor.authoraffiliation[Collado, Antonio] Torrecardenas Univ Hosp, Infect Dis Dept, Almeria, Spain
dc.contributor.authoraffiliation[Martin, Marta Casado] Torrecardenas Univ Hosp, Gastroenterol Dept, Almeria, Spain
dc.date.accessioned2025-01-07T12:49:09Z
dc.date.available2025-01-07T12:49:09Z
dc.date.issued2018-05-01
dc.description.abstractObjectives Anaemia is the most common side effect associated with ribavirin (RBV). This study intended to assess its incidence and determine its predictive factors in patients with hepatitis C virus on RBV plus direct-acting antiviral agents (DAAs).Methods A retrospective study of patients receiving RBV+DAA was conducted. Serum haemoglobin (Hb) was determined at baseline and monitored 4weekly. Anaemia was defined as a single occurrence of Hb
dc.identifier.doi10.1136/ejhpharm-2017-001277
dc.identifier.essn2047-9964
dc.identifier.issn2047-9956
dc.identifier.pmid31157007
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc6452397?pdf=render
dc.identifier.urihttps://hdl.handle.net/10668/24955
dc.identifier.wosID431400800006
dc.issue.number3
dc.journal.titleEuropean journal of hospital pharmacy
dc.journal.titleabbreviationEur. j. hosp. pharm.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.page.number132-137
dc.publisherBmj publishing group
dc.rights.accessRightsopen access
dc.subjectRibavirin
dc.subjectDirect-acting antiviral
dc.subjectAnaemia
dc.subjectPredictor
dc.subjectHepatitis C
dc.subjectPeginterferon
dc.subjectTelaprevir
dc.subjectTherapy
dc.subjectCombination
dc.subjectAlpha-2a
dc.titleAnaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number25
dc.wostypeArticle

Files

Collections

SAS - Hospital Universitario Torrecárdenas

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía